Circulating cell-free DNA (ccfDNA) can be found in various body fluids, i.e., blood (serum and plasma), urine, pleural effusions, and ascites. While ccfDNA predominantly originates from physiological processes, a fraction might be related to pathological events, e.g., cancer. Aberrant DNA methylation, which is considered a hallmark of cancer, can be assessed accurately in ccfDNA. Consequently, DNA methylation testing in body fluids represents a powerful diagnostic tool in the clinical management of malignant diseases. Frequently, however, the total amount of disease-related ccfDNA in a sample is low and masked by an excess of physiological ccfDNA. Thus, DNA methylation analysis of tumor-derived DNA is challenging, and high volumes of body fluids need to be analyzed in order to ensure a sufficient abundance of the analyte in the test sample. DNA methylation assays are usually based on prior conversion of cytosines to uracils by means of bisulfite. This reaction takes place under harsh chemical conditions leading to DNA degradation and therefore necessitates a proper DNA purification before downstream analyses. This article describes a protocol which allows for the preparation of ultra-pure bisulfite-converted DNA from up to 3 ml blood plasma and serum, which is well suited for subsequent molecular biological techniques, e.g., methylation-specific real-time PCR.
DNA methylation Circulating cell-free DNA ccfDNA Biomarker Plasma Serum Blood Body fluid Bodily fluid Bisulfite Magnetic beads Ammonium bisulfite
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Conflict of Interest: Dimo Dietrich is a consultant for AJ Innuscreen GmbH (Berlin, Germany) and receives royalties from product sales (innuCONVERT kits).
Frommer M, McDonald LE, Millar DS et al (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89:1827–1831CrossRefPubMedPubMedCentralGoogle Scholar
Darst RP, Pardo CE, Ai L, et al (2010) Bisulfite sequencing of DNA. Curr Protoc Mol Biol. Chapter 7:Unit 7.9.1–17. doi: 10.1002/0471142727.mb0709s91.
Millar DS, Warnecke PM, Melki JR et al (2002) Methylation sequencing from limiting DNA: embryonic, fixed, and microdissected cells. Methods 27(2):108–113CrossRefPubMedGoogle Scholar
Boyd VL, Zon G (2004) Bisulfite conversion of genomic DNA for methylation analysis: protocol simplification with higher recovery applicable to limited samples and increased throughput. Anal Biochem 326:278–280. doi:10.1016/j.ab.2003.11.020CrossRefPubMedGoogle Scholar
Hayatsu H, Negishi K, Shiraishi M (2004) Accelerated bisulfite-deamination of cytosine in the genomic sequencing procedure for DNA methylation analysis. Nucleic Acids Symp Ser (Oxf) 48:261–262. doi:10.1093/nass/48.1.261CrossRefGoogle Scholar
Hayatsu H, Shiraishi M, Negishi K (2008) Bisulfite modification for analysis of DNA methylation. Curr Protoc Nucleic Acid Chem. Chapter 6:Unit 6.10. doi: 10.1002/0471142700.nc0610s33.
Shiraishi M, Hayatsu H (2004) High-speed conversion of cytosine to uracil in bisulfite genomic sequencing analysis of DNA methylation. DNA Res 11:409–415CrossRefPubMedGoogle Scholar